BRODE CAPITAL S.C.A., SICAV- SIF is an investment company incorporated in the Grand Duchy of Luxembourg in November 2013.
BRODE CAPITAL S.C.A., SICAV- SIF main focus is on investment and strategic development of a wide portfolio of companies in healthcare and pharmaceutical sectors such as pharmacies, its chains, clinical centers, distribution and trade with medical products or healthcare devices, health insurance, research related to healthcare, healthcare and services projects oriented on seniors and ageing of the population needs and similar. The geographical focus of the investment selection process is oriented on EU countries with transparent regulatory and legal environments.
BRODE CAPITAL S.C.A., SICAV- SIF is a private independent company with a Board of Directors consisting of four members. All BRODE Capital investment projects are reviewed by the Board of Directors using a standardized evaluation process. This proven assessment mechanism provides transparent and complex environment for decision making while at the same time minimizes the procedural and realization delays. The members of the Board of Directors are professionals with a backgrounds at identification of investment opportunities, investors’ relations, investment project evaluation and at dealing with financial institutions e.g. on debt financing of equity investment projects.
The investment objective of BRODE CAPITAL S.C.A., SICAV- SIF to generate superior returns and to achieve capital growth from carefully selected equity investments and its strategic management in the medium and long term.
JOSEF TRNKA, CZECH REPUBLIC
He is responsible for the business development, for the identification of investment opportunities and investment and risk management.
He worked for Commerzbank as an Asset Manager responsible for in-house development of solutions regarding structural finance products for major domestic and foreign clients. He is a co-founder of Health Management Consulting a leading center of excellence in healthcare management in Czech Republic.
FRANCK-OLIVIER CERA, LUXEMBOURG
Frenchman living in the Grand Duchy of Luxembourg. He is responsible for strategic fund management.
He represents BRODE Capital by dealing with the providers of the investment and banking services. He worked as a Head of Legal for Private Banking at Société Générale Bank & Trust. From 2012 he works as a Partner in charge of the Banking & Finance Practice of AMMC Law. He has an extensive consulting experience in the private equity and property investment.
JULIEN DIF, LUXEMBOURG
Frenchman living in the Grand Duchy of Luxembourg. He is responsible for risk management and for the conflict of interest policy.
He holds an extensive experience in projects of collective investment and property management. He is a partner in the law firm Bonnard Lawson, which focuses on corporate law, collective investments with an emphasis on the Luxembourg and Swiss investment funds.
RADEK BANÝR, CZECH REPUBLIC
Radek Banýr lives in the Czech Republic. He is responsible for the business development, for the identification of investment opportunities and operational fund management.
He has managed numerous projects in the health sector. He participated in the development of activities of company Linet in the Greater China and Southeast Asia regions. He holds extensive experience in business development in the medical technology and energy efficiency projects.
BRODE CAPITAL INVESTMENT STRATEGY IS CREATED USING THE IN-DEPTH HEALTHCARE MARKET KNOWLEDGE, FINANCIAL MANAGEMENT AND LEGAL EXPERTISE.
The strategic goal of BRODE Capital is creation and management of the diversified portfolio of companies active in the healthcare markets which have well performing management and a major business activity with attractive potential. The BRODE Capital investment policy outlines the key eligible sectors for investments as pharmacies, its chains, clinical centers, distribution and trade with medical products or healthcare devices, health insurance, research related to healthcare, healthcare and services projects oriented on seniors and ageing of the population.
BRODE Capital to build up its portfolio mainly by investing through equity instruments in companies of the above categories or through acquisition of company or enterprise or its part.
The preferred investment horizon is defined from 6 to 10 years.
The Brode A fund (BCA) offers a unique access to defensive sector of healthcare services with solid dynamics and significant growth trend arising mainly from increasing length of life, population ageing, enormous development of technology and ongoing restructuring/ consolidation of the sector (e.g. generation change).
05/2016 Prague - Acquisition of INPHARMEX, spol. s.r.o.
BCA has acquired a company INPHARMEX (INP) which is the owner of a medicinal information system AISLP and a leading provider of information on medicinal products in the Czech Republic. INP is a sole owner and provider of an automated information system on medicinal products (AISLP). The system has been used for the last 25 years by more than 90% of state and private hospitals, 75% of the pharmacies and many other health care facilities, ranging from general practitioners` ambulances to leading university hospitals. Among other users of the medicinal information provided by the AISLP system are spas and rehabilitation centers, senior care facilities, pharmaceutical companies, distributors of medicines and also Armed Forces of the Czech Republic, Police of the Czech Republic or the Fire Rescue Service of the Czech Republic. www.aislp.cz
03/2016 Prague – Completion of AnLab s.r.o. acquisition
BCA has finished an acquisition of a company AnLab s.r.o. (AnL) which is one of the few independent animal health monitoring laboratory in Europe. AnL provides complex and highest quality laboratory diagnostic services such as bacteriology, parasitology and pathology and also delivers laboratory animals and research models. Throughout more than 20 years of its business activities AnL has developed a wide international network of clients in European and other developed countries. www.anlab.cz
10/2015 Prague - OC PHARMA – sell to Dr. Max
The other significant acquisition of BCA is OC PHARMA a.s. (OCP), the Czech company operating a network of pharmacies all over the Czech Republic. As a response to the ongoing consolidation and concentration in this segment of the market BCA sold majority of the pharmacies to the most dominant pharmacy chain Dr. MAX. www.drmax.cz
BRODE Capital S.C.A., SICAV-SIF11 Avenue Emile Reuter
BRODE Czech, s.r.o.Armády 2793/26
155 00 Praha 5